Abstract: Objective: To investigate the effects of c-erbB-2 and c-raf-1 ASODN transfected in combination into the human ovarian carcinoma SKOV₃ cell line and the molecular mechanism involved. Methods: There were 7 groups in our study: control group, c-erbB-2 sense experimental group, c-raf1 sense experimental group, c-erbB-2 antisense experimental group, c-raf-1 antisense experimental group, whole-dose experimental group, and half-dose experimental group. At different timepoints after liposome-mediated transfection, the cell proliferation, apoptosis, and protein expression level were observed by MTT assay, flow cytometry, fluorescent microscopy, cloning test and immunohistochemistry. Results: Seventy-two hours after transfection the whole-dose experimental group and the half-dose experimental group had OD values of 0.151 (P<0.005) and 0.073 (P<0.005), respectively. Compared to the control group, the whole-dose experimental group and the half-dose experimental group had proliferation rates that were 88.7% and 94.5%, respectively. The cloning efficiency was 19.4% (P<0.01) and 12.8% (P<0.01), respectively, and the apoptosis rate was 24.3% (P<0.05) and 31.5% (P<0.01), respectively. Protein levels including c-erbB-2, c-raf-1, PCNA, c-jun, and c-fos were downregulated. Conclusions: The study implies that c-erbB-2 and c-raf-1 combined ASODN transfection is superior to single ASODN for inhibiting proliferation of the human ovarian carcinoma SKOV₃ cell line. It would be realized by regulating down the expression of c-erbB-2, c-raf-1, PCNA, c-jun, c-fos genes.